Table 1.
Baseline characteristics of the 259 patients (pts) and 65 long‐term survivors (LTSs), according to nivolumab treatment duration
| Characteristic |
All pts (N = 259) |
LTSs (n = 65) |
Nivolumab treatment duration | ||
|---|---|---|---|---|---|
|
<2 y (n = 47) |
2 y (n = 7) |
>2 y (n = 11) |
|||
| Median age, y [range] | 62 [29‐85] | 59 [39‐80] | 59 [45‐80] | 52 [39‐72] | 58 [53‐66] |
| Sex, n (%) | |||||
| Female | 72 (27.8) | 17 (26.2) | 12 (25.5) | 2 (28.6) | 3 (27.3) |
| Male | 187 (72.2) | 48 (73.8) | 35 (74.5) | 5 (71.4) | 8 (72.7) |
| Smoking history, n (%) | 222 (90.6) | 57 (87.7) | 39 (83) | 7 (100) | 11 (100) |
| Histology, n (%) | |||||
| Adenocarcinomas | 165 (63.7) | 41 (63.1) | 31 (66.0) | 4 (57.1) | 6 (54.5) |
| Squamous cell | 70 (27.0) | 15 (23.1) | 11 (23.4) | 3 (42.9) | 1 (9.1) |
| Undifferentiated carcinomas | 18 (6.9) | 7 (10.8) | 4 (8.5) | 0 (0) | 3 (27.3) |
| Others | 6 (2.4) | 2 (3.0) | 1 (2.1) | 0 (0) | 1 (9.1) |
| Molecular alterations, n (%) | |||||
| KRAS mutation | 55 (22.0) | 14 (21.5) | 8 (17.0) | 3 (42.9) | 3 (27.3) |
| EGFR mutation | 11 (4.4) | 1 (1.5) | 1 (2.1) | 0 (0) | 0 (0) |
| BRAF mutation | 4 (1.6) | 3 (4.7) | 2 (4.3) | 0 (0) | 1 (9.1) |
| Other or not found | 189 (72) | 47 (72.3) | 36 (76.6) | 4 (57.1) | 7 (63.6) |
| Number of prior lines, median [range] | 1 [1‐6] | 1 [1‐6] | 1 [1‐6] | 1 [1‐2] | 1 [1‐4] |
| BMs before nivolumab onset, n (%) | 77 (29.7) | 22 (33.8) | 14 (29.8) | 3 (42.9) | 5 (45.5) |
| Median nivolumab treatment duration (mo) | 2.3 | 14.5 | 10.6 | 24.2 | 32.3 |
| Median time from diagnosis to nivolumab onset (mo) | 9.8 | 10.9 | 11.3 | 12.8 | 8.1 |
Abbreviations: BMs, brain metastases; BRAF, v‐RAF murine sarcoma viral oncogene homolog B; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat‐sarcoma viral oncogene.